Follow
Pau Castel
Pau Castel
New York University School of Medicine
Verified email at nyulangone.org - Homepage
Title
Cited by
Cited by
Year
Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor
D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ...
Nature 518 (7538), 240-244, 2015
5692015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
3392015
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
E Toska, HU Osmanbeyoglu, P Castel, C Chan, RC Hendrickson, ...
Science 355 (6331), 1324-1330, 2017
2492017
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
F Brasó-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ...
Nature medicine 22 (11), 1303-1313, 2016
2212016
PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition
P Castel, H Ellis, R Bago, E Toska, P Razavi, FJ Carmona, S Kannan, ...
Cancer cell 30 (2), 229-242, 2016
2182016
Somatic PIK3CA mutations as a driver of sporadic venous malformations
P Castel, FJ Carmona, J Grego-Bessa, MF Berger, A Viale, KV Anderson, ...
Science translational medicine 8 (332), 332ra42-332ra42, 2016
1682016
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
JJ Tao, P Castel, N Radosevic-Robin, M Elkabets, N Auricchio, N Aceto, ...
Science signaling 7 (318), ra29-ra29, 2014
1632014
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
F Sanchez-Vega, JF Hechtman, P Castel, GY Ku, Y Tuvy, H Won, CJ Fong, ...
Cancer discovery 9 (2), 199-209, 2019
1272019
Systematic functional characterization of resistance to PI3K inhibition in breast cancer
X Le, R Antony, P Razavi, DJ Treacy, F Luo, M Ghandi, P Castel, ...
Cancer discovery 6 (10), 1134-1147, 2016
1232016
The hVps34‐SGK 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC 1 and tumour growth
R Bago, E Sommer, P Castel, C Crafter, FP Bailey, N Shpiro, J Baselga, ...
The EMBO journal 35 (17), 1902-1922, 2016
1022016
RIT1 oncoproteins escape LZTR1-mediated proteolysis
P Castel, A Cheng, A Cuevas-Navarro, DB Everman, AG Papageorge, ...
Science 363 (6432), 1226-1230, 2019
762019
The present and future of PI3K inhibitors for cancer therapy
P Castel, E Toska, JA Engelman, M Scaltriti
Nature cancer 2 (6), 587-597, 2021
742021
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
D Inoue, JT Polaski, J Taylor, P Castel, S Chen, S Kobayashi, SJ Hogg, ...
Nature genetics 53 (5), 707-718, 2021
732021
PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression
E Toska, P Castel, S Chhangawala, A Arruabarrena-Aristorena, C Chan, ...
Cell reports 27 (1), 294-306. e5, 2019
562019
Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility
A Angulo-Urarte, P Casado, SD Castillo, P Kobialka, MP Kotini, ...
Nature communications 9 (1), 4826, 2018
562018
The duality of human oncoproteins: drivers of cancer and congenital disorders
P Castel, KA Rauen, F McCormick
Nature Reviews Cancer 20 (7), 383-397, 2020
532020
Therapeutic benefit of selective inhibition of p110α PI3-kinase in pancreatic neuroendocrine tumors
A Soler, AM Figueiredo, P Castel, L Martin, E Monelli, A Angulo-Urarte, ...
Clinical Cancer Research 22 (23), 5805-5817, 2016
402016
Angiocrine polyamine production regulates adiposity
E Monelli, P Villacampa, A Zabala-Letona, A Martinez-Romero, J Llena, ...
Nature Metabolism 4 (3), 327-343, 2022
382022
The sixth international RASopathies symposium: precision medicine—from promise to practice
KW Gripp, L Schill, L Schoyer, B Stronach, AM Bennett, S Blaser, A Brown, ...
American Journal of Medical Genetics Part A 182 (3), 597-606, 2020
302020
RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity
P Castel, S Dharmaiah, MJ Sale, S Messing, G Rizzuto, ...
Proceedings of the National Academy of Sciences 118 (33), e2103261118, 2021
262021
The system can't perform the operation now. Try again later.
Articles 1–20